Recurrence of macular edema associated with branch retinal vein occlusion after intravitreal bevacizumab

Japanese Journal of Ophthalmology

Volumn 56, Issue 2, 2012, Pages 165-174

  Hanada, Narihisa ^a   Iijima, Hiroyuki ^a   Sakurada, Yoichi ^a   Imasawa, Mitsuhiro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Branch retinal vein occlusion; Intravitreal bevacizumab; Optical coherence tomography; Recurrence; Retreatment

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; BRANCH RETINAL ARTERY OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA EDEMA; RETINAL THICKNESS; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RECURRENCE; RETINA; RETINAL VEIN OCCLUSION; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84859105784     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-011-0113-4     Document Type: Article

References (26)

1. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-82.
2. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140: 256-61.
3. Ahmadi AA, Chuo JY, Banashkevich A, Ma PE, Maberley DA. The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol. 2009;44:154-9.
4. Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, et al. Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion. Retina. 2009;29:913-25.
5. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:27-33.
6. Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina. 2009;29:1242-8.
7. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol. 2008;92:351-5. (Pubitemid 351363529)
8. Ota M, Tsujikawa A, Miyamoto K, Sakamoto A, Murakami T, Yoshimura N. Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion. Jpn J Ophthalmol. 2010;54:555-64.
9. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27:419-25. (Pubitemid 46624280)
10. Rensch F, Jonas JB, Spandau UH. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica. 2009;223:124-7.
11. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina. 2009;29:511-5.
12. Byun YJ, Roh MI, Lee SC, Koh HJ. Intravitreal triamcinolone acetonide versus bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248:963-71.
13. Cheng KC, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vsbevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye. 2009;23:2023-33.
14. Guthoff R, Meigen T, Hennemann K, Schrader W. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to branch retinal vein occlusion in a pair-matched analysis. Ophthalmologica. 2010;224:319-24.
15. Hou J, Tao Y, Jiang YR, Li XX, Gao L. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study. Chin Med J (Engl). 2009;122:2695-9.
16. Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2009;23:259-65.
17. Badala F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol. 2008;19:234-8. (Pubitemid 351535920)
18. Hoeh AE, Ach T, Schaal KB, Scheuerle AF, Dithmar S. Longterm follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:1635-41.
19. Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab(Avastin) therapy for retinal venous occlusive disease. Retina. 2007;27:426-31. (Pubitemid 46624281)
20. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24: 676-98. (Pubitemid 39391758)
21. Yamashiro K, Tsujikawa A, Miyamoto K, Oh H, Otani A, Tamuara H, et al. Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. Retina. 2010;30:485-90.
22. Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR, et al. Topography of diabetic macular edema with optical coherence tomography. Ophthalmology. 1998;105:360-70. (Pubitemid 28090845)
23. Takahashi H, Iijima H. Sectoral thinning of the retina after branch retinal artery occlusion. Jpn J Ophthalmol. 2009;53:494-500.
24. Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2010;248:155-9.
25. Prager F, Michels S, Kriechbaum K, Georgopoulos M, Funk M, Geitzenauer W, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009;93: 452-6.
26. Wong I, Koo S, Chan C. Effect of intravitreal bevacizumab (IVB) in treating macular edema secondary to branch retinal vein occlusion (BRVO). Retina. 2010;30:710.